Creative Biolabs has introduced an integrated OMV and exosome-boosted CAR-T development platform aimed at investigating strategies to overcome the barriers that have limited CAR-T cell therapy in solid tumors. The announcement matters because CAR-T therapy, while transformative in blood cancers, has struggled to deliver similar benefits in solid tumors due to poor T-cell infiltration through dense tumor stroma, an immunosuppressive tumor microenvironment that drives metabolic exhaustion, and safety concerns such as cytokine release syndrome, alongside antigen heterogeneity and escape. Conventional CAR-T approaches alone have not been able to surmount these barriers simultaneously, so the platform represents an attempt to give researchers a dual-mechanism toolkit for studying them in parallel.
The platform integrates two complementary nanoscale vesicle technologies—bacterial outer membrane vesicles (OMVs) and mammalian-derived exosomes—into a unified, customizable pipeline for vesicle-enabled CAR-T research and tumor-microenvironment modulation. Each vesicle type addresses a distinct bottleneck. The OMV engineering arm functionally remodels the tumor microenvironment to promote CAR-T infiltration. Engineered OMVs can carry selected immunomodulatory or delivery payloads for investigating tumor-microenvironment remodeling and CAR-T infiltration. A standout innovation is the BROAD-CAR system, in which OMVs transiently program tumor cells in vivo to display synthetic antigens recognized by a universal CAR-T construct—providing a preclinical strategy for evaluating antigen redirection across heterogeneous tumor models. Additionally, OMV surface engineering with targeting ligands guides CAR-T homing precision, while detoxified LPS strains require characterization of immunostimulatory activity and endotoxin-related safety, a critical differentiator from synthetic liposome carriers that lack intrinsic immune-activating capacity.
The exosome engineering arm provides a biocompatible support system to sustain CAR-T activity within the suppressive tumor microenvironment. CAR-exosomes—exosomes directly displaying functional CARs on their surface—deliver antigen-specific tumor killing without live cell administration, with a safety profile that requires preclinical comparison with live-cell CAR-T approaches. Selected exosome systems are being investigated for transport across biological barriers, including the blood-brain barrier, and can be engineered to carry cytokines, checkpoint inhibitors, and survival signals intended to modulate CAR-T exhaustion and persistence.
A third service line equips both vesicle types with customized therapeutic payloads. Small molecules, nucleic acids such as mRNA, siRNA, and miRNA, and proteins can be co-encapsulated within a single vesicle for multimodal synergy. Metabolic tumor-microenvironment remodeling formulations alleviate iron-mediated oxidative stress, while vesicle-mediated checkpoint blockade enables localized, sustained PD-1/PD-L1 inhibition directly at tumor sites, maximizing activation while minimizing systemic toxicity. The broader implication is that the platform offers researchers a way to evaluate complementary effects across multiple barriers at once, rather than addressing one obstacle at a time, through an OMV & exosome-boosted CAR-T development platform designed to support simultaneous stroma remodeling and persistence support.
